In the VErA cohort, we have identified a small subgroup of RA patients, who are anti-CCP-negative/ACa-Fib-positive and who have a higher disease activity at disease onset than patients who are immunopositive for anti-CCP antibodies (Figure 5A). The gene discussed is FBL; the disease is rheumatoid arthritis.